Business Wire·May 18, 2026, 8:05 AM ET

Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead

Turn Therapeutics Inc. (NASDAQ: TTRX) appointed Stephen M. Hahn, M.D., former FDA Commissioner, to oversee clinical & regulatory strategy for GX-03.
GX-03 is an investigational topical therapy currently in a Phase 2 trial for moderate-to-severe atopic dermatitis.
Dr. Hahn aims to advance GX-03 as a differentiated, localized treatment that avoids significant systemic effects.
Topline results for the GX-03 Phase 2 trial are expected in mid-2026.
GX-03 is a first-in-class, non-systemic therapy designed to modulate IL-36, IL-4, IL-13, & IL-31 signaling through upstream prevention.
Dr. Hahn served as the 24th FDA Commissioner from 2019 to 2021 & previously led MD Anderson Cancer Center.
Bradley Burnam, CEO of Turn Therapeutics, highlighted Dr. Hahn's unique combination of scientific rigor, regulatory expertise, & patient compassion.
The press release includes forward-looking statements regarding development programs, with risks detailed in the Company's SEC filings.